Management of Chronic Hepatitis C in End-stage Renal Disease

Veronica Angulo-Diaz, Joseph K. Lim, Paul Martin, Ann Marie Liapakis

Research output: Contribution to journalReview article

Abstract

Treatment for chronic viral hepatitis C has advanced dramatically to current standard of care all-oral direct-acting antiviral regimens with relatively short treatment duration and high efficacy. Patients with comorbid end-stage renal disease have constituted a "special patient population" with data and treatment options lagging behind that of the broader population of patients with chronic hepatitis C until recently. Herein we review the current evidence base for direct-acting antiviral therapy in this population. We provide a suggested algorithm for the evaluation of such patients for therapy. We highlight special considerations in regards to the choice of regimen, duration, and timing in regards to potential kidney transplantation.

Original languageEnglish (US)
Pages (from-to)287-294
Number of pages8
JournalJournal of Clinical Gastroenterology
Volume52
Issue number4
DOIs
StatePublished - Jan 1 2018

Fingerprint

Chronic Hepatitis C
Chronic Kidney Failure
Antiviral Agents
Population
Therapeutics
Standard of Care
Kidney Transplantation

Keywords

  • direct-acting antiviral therapy
  • hepatitis C
  • kidney transplant
  • renal insufficiency

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Management of Chronic Hepatitis C in End-stage Renal Disease. / Angulo-Diaz, Veronica; Lim, Joseph K.; Martin, Paul; Liapakis, Ann Marie.

In: Journal of Clinical Gastroenterology, Vol. 52, No. 4, 01.01.2018, p. 287-294.

Research output: Contribution to journalReview article

Angulo-Diaz, Veronica ; Lim, Joseph K. ; Martin, Paul ; Liapakis, Ann Marie. / Management of Chronic Hepatitis C in End-stage Renal Disease. In: Journal of Clinical Gastroenterology. 2018 ; Vol. 52, No. 4. pp. 287-294.
@article{a91b2277c6ed42dbad73a208da05fef4,
title = "Management of Chronic Hepatitis C in End-stage Renal Disease",
abstract = "Treatment for chronic viral hepatitis C has advanced dramatically to current standard of care all-oral direct-acting antiviral regimens with relatively short treatment duration and high efficacy. Patients with comorbid end-stage renal disease have constituted a {"}special patient population{"} with data and treatment options lagging behind that of the broader population of patients with chronic hepatitis C until recently. Herein we review the current evidence base for direct-acting antiviral therapy in this population. We provide a suggested algorithm for the evaluation of such patients for therapy. We highlight special considerations in regards to the choice of regimen, duration, and timing in regards to potential kidney transplantation.",
keywords = "direct-acting antiviral therapy, hepatitis C, kidney transplant, renal insufficiency",
author = "Veronica Angulo-Diaz and Lim, {Joseph K.} and Paul Martin and Liapakis, {Ann Marie}",
year = "2018",
month = "1",
day = "1",
doi = "10.1097/MCG.0000000000000941",
language = "English (US)",
volume = "52",
pages = "287--294",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Management of Chronic Hepatitis C in End-stage Renal Disease

AU - Angulo-Diaz, Veronica

AU - Lim, Joseph K.

AU - Martin, Paul

AU - Liapakis, Ann Marie

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Treatment for chronic viral hepatitis C has advanced dramatically to current standard of care all-oral direct-acting antiviral regimens with relatively short treatment duration and high efficacy. Patients with comorbid end-stage renal disease have constituted a "special patient population" with data and treatment options lagging behind that of the broader population of patients with chronic hepatitis C until recently. Herein we review the current evidence base for direct-acting antiviral therapy in this population. We provide a suggested algorithm for the evaluation of such patients for therapy. We highlight special considerations in regards to the choice of regimen, duration, and timing in regards to potential kidney transplantation.

AB - Treatment for chronic viral hepatitis C has advanced dramatically to current standard of care all-oral direct-acting antiviral regimens with relatively short treatment duration and high efficacy. Patients with comorbid end-stage renal disease have constituted a "special patient population" with data and treatment options lagging behind that of the broader population of patients with chronic hepatitis C until recently. Herein we review the current evidence base for direct-acting antiviral therapy in this population. We provide a suggested algorithm for the evaluation of such patients for therapy. We highlight special considerations in regards to the choice of regimen, duration, and timing in regards to potential kidney transplantation.

KW - direct-acting antiviral therapy

KW - hepatitis C

KW - kidney transplant

KW - renal insufficiency

UR - http://www.scopus.com/inward/record.url?scp=85044296622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044296622&partnerID=8YFLogxK

U2 - 10.1097/MCG.0000000000000941

DO - 10.1097/MCG.0000000000000941

M3 - Review article

VL - 52

SP - 287

EP - 294

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - 4

ER -